We also found that atorvastatin can increase the sensitivity of NSCLC cells to carboplatin by inhibiting protein kinase B (Akt) activation and up-regulating Recombinant Tissue Inhibitors of Metalloproteinase 1 (TIMP1) expression, thus increasing the survival time of NSCLC tumor-bearing mice [8]. Here, AKT1 is linked to non-small cell lung carcinoma.